AstraZeneca's (AZN) Durvalumab Granted FDA Breakthrough Therapy Designation
Tweet Send to a Friend
AstraZeneca (NYSE: AZN) and MedImmune announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
